# Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

> **NCT03168828** · PHASE1 · COMPLETED · sponsor: **Taris Biomedical LLC** · enrollment: 7 (actual)

## Conditions studied

- Neurogenic Detrusor Overactivity

## Interventions

- **DRUG:** Trospium-Releasing Intravesical System (TAR-302-5018)

## Key facts

- **NCT ID:** NCT03168828
- **Lead sponsor:** Taris Biomedical LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-24
- **Primary completion:** 2018-07-26
- **Final completion:** 2018-07-26
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168828, "Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03168828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*